Federal Register Notice: FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet 6/6, from 8 a.m. to 5:30 p.m. at the CDER Conference Room, Rm. 1066, 5630 Fishers Lane, Rockville, MD. The committee will consider the safety and efficacy of a Chiron Corp. NDA for Pulminiq (cyclosporine, inhalation solution) for use in combination with standard immunosuppressive therapy to increase survival and prevent chronic rejection in patients receiving allogenic lung transplants. Contact Teresa A. Watkins, (301) 827-7001. To view this notice, click here.
